SRRA News and Press, Sierra Oncology Inc. From 05/06/22

Sierra Oncology, Inc. (NASDAQ: SRRA), a late-stage biopharmaceutical company with a mission to deliver targeted therapies that treat rare forms of cancer, today reported its financial and operating results for the first quarter ended March 31, 2022. “By entering into a merg...

NEW YORK, NY / ACCESSWIRE / April 29, 2022 / Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: SilverBow Resources, Inc. (NYSE:SBO...

NEW YORK, NY / ACCESSWIRE / April 21, 2022 / Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Tivity Health, Inc. (NASDAQ:TVT...

GlaxoSmithKline has agreed to buy out Sierra Oncology for $1.9bn - Sierra is attempting to bring Momelotinib to market after strong Phase 3 results in Myelofibrosis. Momelotinib could be a blockbuster, with peak sales expectations of $1.7bn. Activist Investor Elliott Management is...

Thoma Bravo continued its binge of software acquisitions last week by entering into an agreement to acquire SailPoint Technologies. Kaseya, a provider of unified IT management and security software, entered into a definitive agreement to acquire Datto Holdings for $6.2 billion. Wi...

5 Top Biotech Stocks To Watch Today The stock market offers plenty of opportunities for investors. Some industries would still catch the attention of investors regardless of the broader market sentiment. A prime example would be biotech stocks . Now, why is that so? For starters...

Palm Beach, FL – April 14, 2022 – FinancialNewsMedia.com News Commentary – CAR-T therapy is a sort of treatment in which a patient’s T cells which is a type of immune system cell, are genetically modified to attack cancer cells in the lab. T cells are...

Stocks rebounded from recent weakness on Wednesday, as bargain hunting among beaten-down growth stocks pushed the major averages higher. The Nasdaq led the advance, climbing about 2% on the day. Travel stocks contributed to the upswing. An upbeat earnings report from Delta Air Lines raised ho...

Sierra Oncology ( NASDAQ: SRRA ) shares traded significantly higher after announcing the acquisition by GlaxoSmithKline PLC ( LON: GSK ) for $55 a share in cash. That represents a total equity value of $1.9 billion, attributed mainly to SRRA’s Momeloti...

Gainers: Kaleido Biosciences (KLDO) +114%. Antares Pharma (ATRS) +49%. Sierra Oncology (SRRA) +39%. HighPeak Energy (HPK) +29%. Biofrontera (BFRI) +30%. Turning Point Therapeutics (TPTX) +27%. Aterian (ATER) +25%. Hallador Energy (HNRG) +23%. Crinetics Pharmaceutical (CRNX) +20%. Exscientia (...